Wells Fargo analyst Yanan Zhu downgraded Aeglea BioTherapeutics to Equal Weight from Overweight with a price target of 35c, down from $2.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AGLE:
- Aeglea BioTherapeutics downgraded to Market Perform at LifeSci Capital
- Aeglea BioTherapeutics price target removed at H.C. Wainwright
- Aeglea BioTherapeutics downgraded to Hold from Buy at JonesResearch
- Aeglea BioTherapeutics exploring strategic alternatives
- Aeglea BioTherapeutics announces interim Phase 1/2 results of pegtarviliase